Abstract
High on-treatment platelet reactivity (HOPR) remains a significant challenge for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). While genetic factors are known to influence clopidogrel response, they do not account for all cases. This study identifies low red blood cell (RBC) counts as a novel, independent predictor of HOPR, offering a potential clinical marker for identifying high-risk patients.
Introduction
Cardiovascular disease remains the leading cause of death globally, with coronary artery disease (CAD) responsible for approximately half of these fatalities. For patients with CAD who undergo percutaneous coronary intervention (PCI), the management of thrombotic risk is paramount. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the standard pharmacological intervention to prevent stent thrombosis and recurrent ischemic events.
Clopidogrel is one of the most widely prescribed P2Y12 inhibitors due to its established efficacy and safety profile. However, a significant clinical challenge persists: up to 30% of patients treated with standard doses of clopidogrel exhibit High On-treatment Platelet Reactivity (HOPR). In these individuals, the medication fails to adequately suppress platelet activity, leaving them at a significantly higher risk for recurrent heart attacks or cardiac death. While polymorphisms in the CYP2C19 gene are recognized contributors to this variability, they explain only about 12% of HOPR cases. Identifying other clinical factors is crucial for refining personalized antiplatelet strategies and addressing this residual ischemic risk.
Methods
This cross-sectional cohort study analyzed 1,649 CAD patients who underwent PCI at the First Affiliated Hospital of Nanjing Medical University. All participants had been on a stable dual antiplatelet regimen of clopidogrel (75 mg/day) and aspirin (100 mg/day) for at least five days prior to testing.
Platelet reactivity was assessed using Light Transmission Aggregometry (LTA), which is considered the clinical gold standard for measuring platelet function. Venous blood samples were collected two hours after drug administration. Platelet aggregation was induced by adenosine diphosphate (ADP) at a final concentration of 5 μmol/L. HOPR was defined as a maximum platelet aggregation (PL<sub>ADP</sub>) exceeding 40%. The research team utilized both univariable and multivariable logistic regression models to identify clinical variables independently associated with poor drug response.
Results
Among the 1,649 patients in the cohort, 23.6% (389 patients) were identified as having HOPR. After adjusting for potential confounders, multivariable analysis identified three key independent predictors of high platelet reactivity:
- Red Blood Cell (RBC) Count: Higher RBC counts were significantly associated with a lower risk of HOPR (OR = 0.480, 95% CI: 0.302–0.763, P = 0.002). This indicates that patients with lower RBC counts are more likely to experience clopidogrel resistance.
- Body Mass Index (BMI): Increased BMI was linked to higher platelet reactivity (OR = 1.140, 95% CI: 1.054–1.232, P = 0.001), possibly due to altered drug metabolism or under-dosing in larger patients.
- Statin Consumption: Patients taking statins were significantly more likely to exhibit HOPR (OR = 4.504, 95% CI: 1.004–20.208, P = 0.049).
Discussion
The inverse relationship between RBC count and platelet reactivity suggests that RBCs play a more active role in hemostasis than previously recognized. The authors propose a biological mechanism involving Nitric Oxide (NO). RBCs are known to produce and release NO, a potent endogenous inhibitor of platelet activation. A reduction in RBC mass might lead to a localized deficiency in NO bioavailability, thereby failing to provide the necessary inhibitory signal to complement the medication's effect.
Furthermore, the association with statins likely stems from competitive inhibition. Both statins and clopidogrel are metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme. Concurrent use may reduce the efficiency of clopidogrel's conversion into its active metabolite, thereby diminishing its antiplatelet efficacy.
Conclusion
Low RBC count is a significant independent predictor of HOPR in CAD patients treated with clopidogrel following PCI. While the absolute differences in RBC counts between groups were subtle, this finding highlights the importance of considering basic hematological parameters when assessing ischemic risk. Future research should investigate whether tailoring antiplatelet therapy—perhaps by utilizing more potent agents like ticagrelor in patients with low RBC counts—can improve clinical outcomes for this high-risk subgroup.
Summary updated